Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2a Double-Blind, Randomized, Parallel Group, Dose-Ranging Study to Assess the Safety and Efficacy of Three Doses of TVGV-1 Vaccine Compared to Its Adjuvant, GPI-0100, in Subjects With Histologically Confirmed HPV Induced Cervical HSIL

NCT02576561 is registered in ClinicalTrials.gov with THEVAX Genetics Vaccine as lead sponsor.

NCT NCT02576561
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02576561 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2a Double-Blind, Randomized, Parallel Group, Dose-Ranging Study to Assess the Safety and Efficacy of Three Doses of TVGV-1 Vaccine Compared to Its Adjuvant, GPI-0100, in Subjects With Histologically Confirmed HPV Induced Cervical HSIL
Lead sponsor
THEVAX Genetics Vaccine
Phase
Phase 2
Overall status
Unknown status
Start date
November 30, 2015
Completion date
September 30, 2018
Enrollment
10 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

high-grade squamous intraepithelial lesions, human papillomavirus